NCT06750575Recruiting
Study to Examine the Effect of the Diuretic Furosemide on the Plasma Levels of Toxins and the Removal of Toxins from the Blood in Patients with Chronic Kidney Disease
The Effect of Furosemide on Protein-Bound Uremic Toxin Plasma Levels and Excretion in Patients with Chronic Kidney Disease
Source: ClinicalTrials.gov · Last updated 27 Dec 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this observational study is to examine the interaction between the diuretic furosemide and certain toxins called protein-bound uremic toxins (PBUTs) in patients with chronic kidney disease (CKD). The main question it aims to answer is: what is the effect of furosemide on plasma levels of PBUTs in patients with CKD? Besides, the investigators will also look at the effect of furosemide on the excretion of PBUTs via the urine. Participants will be included in the study once they will be prescribed furosemide as part of routine patient care. Before they start with the furosemide treatment, patients will undergo the following: * Blood pressure measurement * Blood sample withdrawal * Urine sample collection * 12-hour urine collection Then, one to four weeks after starting with furosemide treatment, patients will undergo the following: * Blood pressure measurement * Blood sample prior to furosemide intake (Tmin) * Blood sample withdrawal 90 minutes after furosemide intake (Tmax: time at which the highest furosemide plasma level is expected) * Urine sample collection 60-120 minutes after furosemide intake * 12-hour urine collection The investigators expect furosemide to increase plasma levels of PBUTs by decreasing the renal excretion of the toxins.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 34 (estimated)
- First submitted
- 17 Oct 2024
- Start date
- 10 Jun 2024
- Primary completion date
- 1 Jul 2025
- Lead sponsor
- UMC Utrecht
- Diseases
- Chronic kidney disease
- NCT number
- NCT06750575
What you commit to
- Study type: Observational
- Planned participants: 34
- From 10 Jun 2024 to the primary completion date, 1 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who receive any type of renal replacement therapy (peritoneal dialysis, haemodialysis)
- Patients who will start with medication simultaneously with start of furosemide treatment that might interfere with PBUT excretion or PBUT protein binding
Other illness
- Patients with a liver disease with hyperbilirubinemia
- Patients with end-stage renal failure without residual diuresis
Other
- Patients who are already on furosemide treatment
- Patients who are incapacitated
Who the study is looking for
- An age of 18 years or older
- An eGFR \<60 mL/min/1.73m2 for at least three months (diagnosis of CKD stage 3-5)
- An indication for the start of treatment with furosemide as part of routine patient care
- Willingness to participate in the study and a signed informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Medical Center Utrecht(UMCU) Coordinator of this site? Confirm its status | Utrecht | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.